Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan
Author:
Nakane Keita1ORCID, Taniguchi Kazuki2, Nezasa Minori3, Enomoto Torai13, Yamada Toyohiro4, Tomioka-Inagawa Risa5, Niwa Kojiro6, Tomioka Masayuki17, Ishida Takashi8, Nagai Shingo9, Yokoi Shigeaki10, Taniguchi Tomoki1ORCID, Kawase Makoto1ORCID, Kawase Kota1, Iinuma Koji1, Tobisawa Yuki1, Koie Takuya1ORCID
Affiliation:
1. Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan 2. Department of Urology, Gifu Prefectural General Medical Center, Gifu 5008717, Japan 3. Department of Urology, Matsunami General Hospital, Gifu 5016062, Japan 4. Department of Urology, Ogaki Municipal Hospital, Ogaki 5038502, Japan 5. Department of Urology, Japanese Red Cross Takayama Hospital, Takayama 5068550, Japan 6. Department of Urology, Daiyukai Daiichi Hospital, Ichinomiya 4918551, Japan 7. Department of Urology, Chuno Kosei Hospital, Seki 5013802, Japan 8. Department of Urology, Gifu Municipal Hospital, Gifu 5008513, Japan 9. Department of Urology, Toyota Memorial Hospital, Toyota 4718513, Japan 10. Department of Urology, Central Japan International Medical Center, Minokamo 5058510, Japan
Abstract
Randomized phase III trial results have demonstrated enfortumab vedotin (EV), an antibody–drug conjugate (ADC) consisting of an anti-Nectin-4 human IgG1 monoclonal antibody and monomethyl auristatin E, is a useful treatment for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) that progressed after immune checkpoint inhibitor (ICI) therapies. This multicenter retrospective cohort study aimed to identify predictive factors for the efficacy of EV therapy and prolonged overall survival (OS) of patients in clinical practice. This study included patients with la/mUC who received ICI treatment. Patients who subsequently received EV treatment, those who received non-EV chemotherapy, and those who received no treatment were defined as EV, non-EV, and best supportive care (BSC) groups, respectively. The median OS was 20, 15, and 7 months in the EV, non-EV, and BSC groups, respectively (p < 0.001). Patients with la/mUC who had a complete or partial response after EV treatment had a significantly prolonged OS compared with those with stable or progressive disease. Univariate analysis showed age, neutrophil-to-lymphocyte ratio (NLR), dysgeusia, and rash as independent predictors of OS improvement. NLR and dysgeusia were independent predictors of OS after EV in multivariate analysis. Patients without these factors had a significantly prolonged OS compared to those with both factors. In real-world practice, EV therapy is an effective treatment for patients with la/mUC after ICI treatment.
Reference33 articles.
1. Cancer statistics, 2024;Siegel;CA Cancer J. Clin.,2024 2. (2024, June 01). Cancer Stat Facts: Bladder Cancer. NIH NCI: Surveillance, Epidemiology, and End Results Program, Available online: https://seer.cancer.gov/statfacts/html/urinb.html. 3. (2024, June 01). Bladder Cancer. NCCN Guidelines 2024. Available online: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. 4. Tomioka-Inagawa, R., Nakane, K., Enomoto, T., Tomioka, M., Taniguchi, T., Ishida, T., Ozawa, K., Takagi, K., Ito, H., and Takeuchi, S. (2022). The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma. Biomedicines, 10. 5. Yamada, T., Nakane, K., Enomoto, T., Tomioka, M., Taniguchi, T., Ishida, T., Ozawa, K., Takagi, K., Ito, H., and Takeuchi, S. (2022). Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study. Biomedicines, 10.
|
|